The weeks following the US Food and Drug Administration’s publication of a draft guidance on manufacturing quality for eye drops and other topical ophthalmic products provided further proof the document was needed.
Since providing the draft guidance on quality considerations for ophthalmic drugs including solutions, suspensions, emulsions, gels, ointments and creams intended...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?